FR3099156B1 - Inhibiteurs selectifs du transporteur bcrp/abcg2 utilises comme agents pour abolir la resistance aux anticancereux - Google Patents

Inhibiteurs selectifs du transporteur bcrp/abcg2 utilises comme agents pour abolir la resistance aux anticancereux Download PDF

Info

Publication number
FR3099156B1
FR3099156B1 FR1908485A FR1908485A FR3099156B1 FR 3099156 B1 FR3099156 B1 FR 3099156B1 FR 1908485 A FR1908485 A FR 1908485A FR 1908485 A FR1908485 A FR 1908485A FR 3099156 B1 FR3099156 B1 FR 3099156B1
Authority
FR
France
Prior art keywords
bcrp
selective
agents
inhibitors used
transporter inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1908485A
Other languages
English (en)
Other versions
FR3099156A1 (fr
Inventor
Ahcène Boumendjel
Pierre Falson
Alexis Moreno
Basile Peres
Emile Roussel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite Claude Bernard Lyon 1 UCBL
Universite Grenoble Alpes
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite Claude Bernard Lyon 1 UCBL
Universite Grenoble Alpes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1908485A priority Critical patent/FR3099156B1/fr
Application filed by Centre National de la Recherche Scientifique CNRS, Universite Claude Bernard Lyon 1 UCBL, Universite Grenoble Alpes filed Critical Centre National de la Recherche Scientifique CNRS
Priority to US17/629,966 priority patent/US20220267289A1/en
Priority to PCT/IB2020/055168 priority patent/WO2021014229A1/fr
Priority to JP2022505245A priority patent/JP2022541334A/ja
Priority to EP20742915.0A priority patent/EP4003969A1/fr
Priority to CN202080053589.5A priority patent/CN114206904A/zh
Priority to CA3148804A priority patent/CA3148804A1/fr
Publication of FR3099156A1 publication Critical patent/FR3099156A1/fr
Application granted granted Critical
Publication of FR3099156B1 publication Critical patent/FR3099156B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/24—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/66—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INHIBITEURS SELECTIFS DU TRANSPORTEUR BCRP/ABCG2 UTILISE COMME AGENTS POUR ABOLIR LA RESISTANCE AUX ANTICANCEREUX La présente invention porte sur un composé de formule (I) : (I) ou énantiomère, sel, solvate ou promédicament pharmaceutiquement acceptable de ce composé, ou un mélange de ceux-ci, le noyau A, et les substituants Z, Y et R1 étant tels que définis dans la présente demande.
FR1908485A 2019-07-25 2019-07-25 Inhibiteurs selectifs du transporteur bcrp/abcg2 utilises comme agents pour abolir la resistance aux anticancereux Active FR3099156B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR1908485A FR3099156B1 (fr) 2019-07-25 2019-07-25 Inhibiteurs selectifs du transporteur bcrp/abcg2 utilises comme agents pour abolir la resistance aux anticancereux
PCT/IB2020/055168 WO2021014229A1 (fr) 2019-07-25 2020-06-01 Inhibiteurs selectifs du transporteur bcrp/abcg2 utilises comme agents pour abolir la resistance aux anticancereux
JP2022505245A JP2022541334A (ja) 2019-07-25 2020-06-01 抗がん剤への耐性を消失させるための剤としての選択的ｂｃｒｐ／ａｂｃｇ２トランスポーター阻害剤
EP20742915.0A EP4003969A1 (fr) 2019-07-25 2020-06-01 Inhibiteurs selectifs du transporteur bcrp/abcg2 utilises comme agents pour abolir la resistance aux anticancereux
US17/629,966 US20220267289A1 (en) 2019-07-25 2020-06-01 Selective bcrp/abcg2 transporter inhibitors as agents to abolish resistance to anti-cancer agents
CN202080053589.5A CN114206904A (zh) 2019-07-25 2020-06-01 选择性bcrp/abcg2转运蛋白抑制剂作为消除抗癌药物耐药性的药物
CA3148804A CA3148804A1 (fr) 2019-07-25 2020-06-01 Inhibiteurs selectifs du transporteur bcrp/abcg2 utilises comme agents pour abolir la resistance aux anticancereux

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1908485 2019-07-25
FR1908485A FR3099156B1 (fr) 2019-07-25 2019-07-25 Inhibiteurs selectifs du transporteur bcrp/abcg2 utilises comme agents pour abolir la resistance aux anticancereux

Publications (2)

Publication Number Publication Date
FR3099156A1 FR3099156A1 (fr) 2021-01-29
FR3099156B1 true FR3099156B1 (fr) 2022-01-28

Family

ID=67999957

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1908485A Active FR3099156B1 (fr) 2019-07-25 2019-07-25 Inhibiteurs selectifs du transporteur bcrp/abcg2 utilises comme agents pour abolir la resistance aux anticancereux

Country Status (7)

Country Link
US (1) US20220267289A1 (fr)
EP (1) EP4003969A1 (fr)
JP (1) JP2022541334A (fr)
CN (1) CN114206904A (fr)
CA (1) CA3148804A1 (fr)
FR (1) FR3099156B1 (fr)
WO (1) WO2021014229A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113480410A (zh) * 2021-07-07 2021-10-08 南京伊派森化学科技有限公司 一种2，4-二溴苯甲醇的合成方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0609420A2 (pt) * 2005-03-30 2010-03-30 Yakult Honsha Kk inibidor de bcrp/abcg2
US20090208493A1 (en) * 2007-11-27 2009-08-20 Stc. Unm Compounds and methods for the selective inhibition of ABCB1, ABCC1 and ABCG2 transporters and the treatment of cancers, especially drug resistant cancers and high throughput flow cytometry assay to detect selective inhibitors
TW200927107A (en) * 2007-12-03 2009-07-01 Yakult Honsha Kk ABCG2 inhibitor

Also Published As

Publication number Publication date
US20220267289A1 (en) 2022-08-25
CN114206904A (zh) 2022-03-18
JP2022541334A (ja) 2022-09-22
CA3148804A1 (fr) 2021-01-28
WO2021014229A1 (fr) 2021-01-28
EP4003969A1 (fr) 2022-06-01
FR3099156A1 (fr) 2021-01-29

Similar Documents

Publication Publication Date Title
MA42341A1 (fr) Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale
MA43400A (fr) Dérivés de phényle en tant qu'agonistes du récepteur cannabinoïde 2
MA38390A1 (fr) Composés tétrahydropyrrolothiazines
MA38540B1 (fr) Dérivés de naphtyridine utiles comme antagonistes de l'intégrine alpha-v-bêta-6
AR105238A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
MA38472A1 (fr) Composé peptidique
EA201791563A1 (ru) Замещенные нуклеозидные производные, полезные в качестве агентов против рака
EA201791873A1 (ru) Полиморф ингибиторов syk
EA202091893A1 (ru) Новые кристаллические формы
MA39784A (fr) Combinaisons des inhibiteurs du fgfr et du cmet destinées au traitement du cancer
MA32171B1 (fr) Compose heterocyclique
MA39335A1 (fr) Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone
MA38583B1 (fr) Dérivés de dolastatine 10 et d'auristatines
EA201891870A1 (ru) Производные иминотиадиазинандиоксида в качестве ингибиторов плазмепсина v
UA122882C2 (uk) Синтез індазолів
FR3099156B1 (fr) Inhibiteurs selectifs du transporteur bcrp/abcg2 utilises comme agents pour abolir la resistance aux anticancereux
EP4122924A3 (fr) Composants et leur utilisation dans des réactions de métathèse
EA201590621A1 (ru) Ингибиторы аггреканазы
MA56508B1 (fr) Inhibiteur de l'egfr pour le traitement du cancer
MA38410A1 (fr) Composés d'azétidinyloxyphénylpyrrolidine
MA39305A3 (fr) Dérivés d'éthynyle
MA41885B1 (fr) Mélange d'additifs
CY1113251T1 (el) Παραγωγα σουλφονυλ-κινολινης
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain
EA201500483A1 (ru) Усовершенствованные способы получения 1-арил-5-алкилпиразоловых соединений

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20210129

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

TQ Partial transmission of property

Owner name: UNIVERSITE CLAUDE BERNARD LYON 1, FR

Effective date: 20220705

Owner name: CNRS - CENTRE NATIONAL DE LA RECHERCHE SCIENTI, FR

Effective date: 20220705

Owner name: UNIVERSITE GRENOBLE ALPES, FR

Effective date: 20220705

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6